Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
Recruiting · NCT06518837 · Registry updated 2026-01-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer | Body Weight, Body Weight Changes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss, hormone receptor-positive breast cancer | Recruiting | Phase 2 | 2026-01-21 | NCT06518837 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ludwig Institute for Cancer Research | 4 |
| Rutgers, The State University of New Jersey | 154 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Rutgers Cancer Institute | New Brunswick | United States | 41 |
| RWJ Barnabas Health - Robert Wood Johnson University Hospital, Hamilton | Hamilton | United States | 1 |
| RWJ Barnabas Health - Robert Wood Johnson University Hospital, Somerset | Somerville | United States | 1 |
| RWJBarnabas Health - Cooperman Barnabas, Livingston | Livingston | United States | 1 |
| RWJBarnabas Health - Monmouth Medical Center | Long Branch | United States | 7 |
| RWJBarnabas Health - Newark Beth Israel Medical Center | Newark | United States | 7 |
| Trinitas Comprehensive Cancer Center | Elizabeth | United States | 1 |